Time filter

Source Type

Zuiga J.,Instituto Nacional Of Enfermedades Respiratorias Ismael Cosio Villegas | Torres-Garcia D.,Instituto Nacional Of Enfermedades Respiratorias Ismael Cosio Villegas | Santos-Mendoza T.,Instituto Nacional Of Enfermedades Respiratorias Ismael Cosio Villegas | Rodriguez-Reyna T.S.,Instituto Nacional Of Ciencias Medicas Y Nutricin Salvador Zubiran | And 2 more authors.
Clinical and Developmental Immunology | Year: 2012

Mycobacterium tuberculosis (Mtb) infection is a major international public health problem. One-third of the world's population is thought to have latent tuberculosis, a condition where individuals are infected by the intracellular bacteria without active disease but are at risk for reactivation, if their immune system fails. Here, we discuss the role of nonspecific inflammatory responses mediated by cytokines and chemokines induced by interaction of innate receptors expressed in macrophages and dendritic cells (DCs). We also review current information regarding the importance of several cytokines including IL-17/IL-23 in the development of protective cellular and antibody-mediated protective responses against Mtb and their influence in containment of the infection. Finally, in this paper, emphasis is placed on the mechanisms of failure of Mtb control, including the immune dysregulation induced by the treatment with biological drugs in different autoimmune diseases. Further functional studies, focused on the mechanisms involved in the early host-Mtb interactions and the interplay between host innate and acquired immunity against Mtb, may be helpful to improve the understanding of protective responses in the lung and in the development of novel therapeutic and prophylactic tools in TB. Copyright © 2012 Joaquin Zuiga et al.

Furuzawa-Carballeda J.,Instituto Nacional Of Ciencias Medicas Y Nutricin Salvador Zubiran | Lima G.,Instituto Nacional Of Ciencias Medicas Y Nutricin Salvador Zubiran | Llorente L.,Instituto Nacional Of Ciencias Medicas Y Nutricin Salvador Zubiran | Nunez-Alvarez C.,Instituto Nacional Of Ciencias Medicas Y Nutricin Salvador Zubiran | Ruiz-Ordaz B.H.,National University of Costa Rica
The Scientific World Journal | Year: 2012

Objectives. Polymerized-type I collagen (polymerized collagen) is a downmodulator of inflammation and cartilage regenerator biodrug. Aim. To evaluate the effect of intraarticular injections of polymerized collagen after arthroscopic lavage on inflammation and clinical improvement in patients with knee osteoarthritis (OA). Methods. Patients (n=19) were treated with 6 intraarticular injections of 2mL of polymerized collagen (n=10) or 2mL of placebo (n=9) during 3 months. Followup was 3 months. The primary endpoints included Lequesne index, pain on a visual analogue scale (VAS), WOMAC, analgesic usage, the number of Tregs and proinflammatory/anti-inflammatory cytokine-expressing peripheral cells. Secondary outcomes were Likert score and drug evaluation. Clinical and immunological improvement was determined if the decrease in pain exceeds 20mm on a VAS, 20 of clinical outcomes, and inflammatory parameters from baseline. Urinary levels of C-terminal crosslinking telopeptide of collagen type II (CTXII) and erythrocyte sedimentation rate (ESR) were determined. Results. Polymerized collagen was safe and well tolerated. Patients had a statistically significant improvement (P0.05) from baseline versus polymerized collagen and versus placebo at 6 months on Lequesne index, VAS, ESR, Tregs IL-1, and IL-10 peripheral-expressing cells. Urinary levels of CTXII were decreased 44 in polymerized collagen versus placebo. No differences were found on incidence of adverse events between groups. Conclusion. Polymerized collagen is safe and effective on downregulation of inflammation in patients with knee OA. © 2012 Janette Furuzawa-Carballeda et al.

Discover hidden collaborations